| Literature DB >> 24960485 |
George E Theodoropoulos1, Theodoros Karantanos2.
Abstract
BACKGROUND AND OBJECTIVES: This review focuses on health-related quality-of-life (HRQoL) assessment questionnaires and the influence of various parameters on HRQoL at distinct time points after laparoscopic colectomy for cancer.Entities:
Mesh:
Year: 2014 PMID: 24960485 PMCID: PMC4035632 DOI: 10.4293/108680813X13753907291152
Source DB: PubMed Journal: JSLS ISSN: 1086-8089 Impact factor: 2.172
Summary of Studies Referring to HRQoL After Laparoscopic Colectomy for Cancer
| Authors | Type of Study | No. of Patients | Type of Cancer | Conversion Rate | HRQoL Measures | Assessment Time Points | |
|---|---|---|---|---|---|---|---|
| Lapa | Opena | ||||||
| Psaila et al,[ | Nonrandomized comparative | 25 | 29 | Colorectal cancer | 12% | SF-36a | Baseline, 2 and 4 mo |
| Schwenk et al,[ | Randomized clinical trial | 30 | 30 | Colorectal cancer | 3.3% | PCAa, VASCa, VASFa, VASRa | First POD–fourth PODa |
| Weeks et al,[ | Randomized clinical trial | 228 | 221 | Colon cancer | 25.7% | QLIa, SDSa, global QoL | Baseline, second POD, 2 wk, 8 wk |
| Adachi et al,[ | Retrospective comparative | 26 | 87 | Colon cancer | NRa | 9-item questionnaire | 1 y |
| Sokolovic et al,[ | Retrospective comparative | 196 | 131 | Colon cancer | NR | SF-36 | 2–3.5 y |
| Guillou et al,[ | Randomized clinical trial | 526 | 268 | Colorectal cancer | 29% | EORTC QLQa-C30, EORTC QLQ-CR38 | Baseline, 2 and 12 wk |
| Yang et al,[ | Nonrandomized comparative | 125 | 103 | Low rectal cancer | NR | EORTC QLQ-C30, EORTC QLQ-CR38 | Baseline, 3–6 mo, 12–18 mo, 2–5 y |
| Breukink et al,[ | Observational prospective | 51 | Rectal cancer | 0% | SF-36, EORTC QLQ-C30, EORTC QLQ-CR38 | Baseline; 3, 6, and 12 mo | |
| Janson et al,[ | Randomized clinical trial | 130 | 155 | Colon cancer | 17.7% | EORTC QLQ-C30, EQ-5Da | 2, 4, and 12 wk |
| Braga et al,[ | Randomized clinical trial | 83 | 85 | Rectal cancer | 0% | SF-36 | 1, 2, and 4 y |
| Staudacher et al,[ | Nonrandomized comparative | 108 | 79 | Rectal cancer | 12% | SF-36 | Baseline, 1 y |
| Jayne et al,[ | Randomized clinical trial | 696 (2:1 randomization) | Colorectal cancer | 38% (first year of study), 16% (sixth year of study) | EORTC QLQ-C30, EORTC QLQ-CR38 | Baseline; 6, 18, and 36 mo | |
| Gameiro et al,[ | Nonrandomized comparative | 20 | 22 | Colorectal cancer | NR | BSKEa, SF-12a, BSIa | Second and fourth POD |
| King et al,[ | Randomized clinical trial | 41 | 19 | Colorectal cancer | NR | EORTC QLQ-C30, EORTC QLQ-CR38 | Baseline; 3, 6, and 12 mo |
| Scarpa et al,[ | Retrospective matched comparative | 21 | 21 | Colorectal cancer | NR | SF-36, BIQa | 3 mo |
| Li et al,[ | Nonrandomized comparative | 11 | 65 | Rectal cancer | 16.9% | EORTC QLQ-C30, EORTC QLQ-CR38 | Baseline, 1 wk, 3 mo, 12 mo |
| Stucky et al,[ | Randomized clinical trial | 230 | 219 | Colon cancer | 25.7% | SDS, QLI | Baseline, 2 wk, 2 mo, 18 mo |
| Vlug et al,[ | Randomized clinical trial | 216 | 211 | Colon cancer | 11.5% | SF-36, GIQLIa | Baseline, 2 and 4 wk |
| Ince et al,[ | Observational prospective | 166 | Colorectal cancer, diverticulitis, Crohn disease, ulcerative colitis | NR | SF-36 | Baseline, 4 wk | |
| Theodoropoulos et al,[ | Observational prospective | 85 | Colorectal cancer | NR | SF-36, EORTC QLQ-C30, EORTC QLQ-CR29, GIQLI | Baseline; 1, 3, 6, and 12 mo | |
Conversion rates refer to patients who underwent laparoscopic colectomy.
BIQ = body image questionnaire; BSKE = Befindlichkeitsskalierung anhand von Kategorien und Eigenschaftswörtern; BSI = Brief Symptom Inventory; EQ-5D = EuroQoL-5D; GIQLI = Gastrointestinal Quality Life Index; Lap = patients who underwent laparoscopic colectomy; NR = not reported; Open = patients who underwent open colectomy; PCA = patient-controlled analgesia; SF-12 = Short Form 12; VASC = visual analog scale for pain while coughing; VASF = visual analog scale for fatigue; VASR = visual analog score at rest.